bioMerieux (BMXMF)
(Delayed Data from OTC)
$105.69 USD
0.00 (0.00%)
Updated Apr 23, 2024 02:30 PM ET
4-Sell of 5 4
C Value C Growth C Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
BMXMF 105.69 0.00(0.00%)
Will BMXMF be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for BMXMF based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BMXMF
Progyny (PGNY) Soars to 52-Week High, Time to Cash Out?
BMXMF: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for BMXMF
bioMerieux initiated with bullish view at Deutsche Bank, here's why
bioMerieux just upgraded at Berenberg, here's why
bioMerieux price target lowered by EUR 1 at Morgan Stanley
Oddo BHF gets more bearish on bioMerieux, downgrades shares
Q3 2023 Biomerieux SA Corporate Sales Call Transcript